Should I Buy LQDA? LQDA 2026 Analysis

Should You Buy Liquidia Corp (LQDA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

43.030

1 Day change

2.67%

52 Week Range

44.270

Analysis Updated At

2026/01/26

Liquidia Corp (LQDA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including impressive Q3 earnings, early profitability, and significant revenue growth driven by Yutrepia. Despite insider selling and pending patent litigation risks, the long-term growth potential outweighs the negatives.

Technical Analysis

The technical indicators are generally bullish. The MACD is above zero and positively contracting, suggesting upward momentum. RSI is neutral at 70.487, and the moving averages (SMA_5 > SMA_20 > SMA_200) confirm a bullish trend. Key resistance levels are at 41.884 and 44.964, with support at 36.899 and 31.914.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Options data indicates a slightly bearish sentiment in the short term, with a higher put-call volume ratio (1.32). However, the open interest put-call ratio of 0.69 suggests a more balanced outlook.

Technical Summary

Sell

Buy

Positive Catalysts

Analysts have raised price targets significantly, with a consensus Buy rating.
Exceptional Q3 financial performance, including a 1121.72% YoY revenue increase and early profitability.
Strong performance of Yutrepia, with peak sales estimates increased to $2B.
Bullish sentiment from analysts citing easing new-patient restrictions and major PBM contracts.

Neutral/Negative Catalysts

Insider selling has increased by 5604.41% over the last month.
Pending patent litigation risks could narrow Yutrepia's indication statement.
Short-term stock trend analysis predicts a potential decline of -1.17% in the next week and -2.16% in the next month.

Financial Performance

Liquidia reported impressive Q3 2025 financials with revenue of $54.34M, up 1121.72% YoY. However, net income dropped to -$3.53M, down -84.74% YoY, and EPS fell to -$0.04. Gross margin improved significantly to 94.16%, up 45.26% YoY, reflecting strong operational efficiency.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are highly bullish on LQDA. H.C. Wainwright raised the price target to $50, Raymond James to $47, BofA to $39, and Jefferies to $45. Analysts highlight early profitability, strong Yutrepia performance, and significant revenue growth as key drivers for their positive outlook.

8 Analyst Rating

Wall Street analysts forecast LQDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LQDA is 47.5 USD with a low forecast of 31 USD and a high forecast of 67 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 41.910

Low

Averages

47.5

High

Current: 41.910

Low

Averages

47.5

High

H.C. Wainwright

Buy

maintain

$35 -> $50

AI Analysis

2025-11-04

Reason

H.C. Wainwright

Price Target

$35 -> $50

AI Analysis

2025-11-04

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Liquidia to $50 from $35 and keeps a Buy rating on the shares. The firm says the company's profitability "arrived early" with Liquidia reporting "impressive" Q3 earnings. The investment story "has shifted from a binary launch to a profit driven story," the analyst tells investors in a research note.

Raymond James

Strong Buy

maintain

$41 -> $47

2025-11-04

Reason

Raymond James

Price Target

$41 -> $47

2025-11-04

maintain

Strong Buy

Reason

Raymond James raised the firm's price target on Liquidia to $47 from $41 and keeps a Strong Buy rating on the shares. Liquidia's Q3 earnings were driven by strong Yutrepia performance in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, with net sales of $51.7M, over triple consensus estimates, and profitability achieved ahead of schedule, the analyst tells investors in a research note. Yutrepia accounted for roughly 75% of revenue growth in its market, aided by major PBM contracts and easing new-patient restrictions. Unadjusted peak sales estimates have been raised to about $2B from $1.1B, reflecting exceptional early launch momentum.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LQDA

Unlock Now

LQDA Should I Buy

LQDA Should I Buy

Should You Buy Liquidia Corp (LQDA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch